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Abstract 
Resveratrol, a naturally occurring phytoalexin, has long been known to have an important 
regulatory role of key functions in cell physiology. This multifunctional role of resveratrol is 
explained by its ability to interact with several targets of various cell pathways. In the recent past, 
synthetic chemical modifications have attempted to enhance the biological effects of resveratrol, 
including their anti-cancer properties. In this study, we investigated the molecular mechanisms of 
action of novel trans-restricted analogues of resveratrol in which the C–C double bond of the 
natural derivative has been replaced by diaryl substituted imidazole analogues. 
In ovarian cancer models, results of in vitro screening revealed that analogues exhibited enhanced 
anti-proliferative properties compared with resveratrol. We found that resveratrol analogues also 
significantly inhibited Akt and MAPK signalling and reduced migration of IL-6 and EGF-treated 
cells. Finally, in ascites-derived cancer cells, we demonstrated that resveratrol analogues reduced 
the expression of epithelial mesenchymal transition (EMT) markers. Collectively, these findings 
indicated the enhanced anti-cancer properties of resveratrol analogues. 
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Introduction 
The health benefits of dietary phytochemicals have been largely demonstrated. Evidence from 
epidemiological studies, animal and human trials has suggested a strong association between the 
consumption of plant nutrients and the prevention of several human diseases including cancer, 
neurological disorders, obesity and atherosclerotic cardiovascular diseases.
1-3
 The beneficial effects 
of dietary compounds have been attributed to the presence of several classes of molecules classified 
as carotenoids, phenolics, alkaloids, nitrogen-containing compounds, and organosulfur compounds.
4
 
Among these, phenolics are molecules possessing at least one aromatic ring with one or more 
hydroxyl groups into the phenyl ring with the potential to interact with cellular proteins. For this 
property, this class of metabolites is the subject of an extensive medical research for its ability to act 
as antioxidants and as anticancer agents via regulation of signal transduction pathways. Resveratrol 
(3,5,4'-trans-trihydroxystilbene) is a naturally occurring phenolic compound that is found in a 
variety of food sources, including wine, soy, peanuts, and peanut products.
5,6
 Since 1997 when Jang 
and colleagues reported the ability of resveratrol to inhibit carcinogenesis at multiple stages,
7
 this 
molecule has gained particularly attention due to its inhibition of cellular events associated with 
tumor initiation, promotion and progression.
8
 The cellular mechanisms contributing to the 
beneficial effects of resveratrol include the inactivation of multiple cellular pathways that regulate 
cell survival or apoptosis. Mechanisms include the downregulation of protein kinases including 
nuclear factor (NF)-κB, Wnt/β-catenin, protein kinase B (Akt), and mitogen-activated protein 
kinases (MAPK).
9-11
 Parametric analysis of gene set enrichment (PAGE) indicated that resveratrol 
caused a significant alteration in 127 pathways including those involved in the regulation of cellular 
metabolism and Stat3 signalling.
8
 
These observations clearly reported the potential application of resveratrol in a clinical setting. 
However, results obtained in vitro were only partially reported in vivo.
12
 A major challenge that 
limits the potential application of resveratrol in human studies is represented by its poor 
bioavailability and the discrepancy between the concentrations used in cellular studies and those 
applied in vivo. Therefore, studies are ongoing to enhance the bioavailability of resveratrol by 
combinations with agents that can increase the in vivo metabolism, nanoparticle-mediated delivery, 
and the development of resveratrol based analogues.
13,14 
In this paper, we designed new analogues of resveratrol in which their stereochemically defined 
"trans" carbon-carbon double bond(s) has been locked into (hetero)cyclic moieties.
15
 This strategic 
choice is founded on the fact that in the conversion of resveratrol into biologically inactive 
metabolites in vivo, the chemical liability of these double bonds, which suffer from trans-to-cis 
stereoisomerization and reduction to saturated carbon-carbon bonds, is involved.
16,17
 In detail, we 
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plan to replace the trans-configured carbon-carbon double bond(s) of resveratrol scaffolds with 
five-membered heterocycles. In order to keep the trans geometry of the leading phytochemicals, the 
aromatic substituents were attached to the heterocyclic core in a 1,3-fashion.  
The anti-tumorigenic activity of all these compounds was evaluated in the ovarian cancer cell line 
SKOV-3 and primary cancer cells isolated from the ascites of patients with metastatic ovarian 
cancer, and compared to that of resveratol. The abilities of these new derivates to reduce cell 
adhesion, cell migration and their potential synergy with chemotherapeutic drugs were also tested. 
The tested derivates were shown to possess greater anti-tumorigenic properties than resveratrol. 
This lays the foundation for future exploration in preclinical models. 
 
 
Experimental 
 
Compounds and reagents 
Collagen type IV, MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide), and 
resveratrol were purchased from Sigma-Aldrich (St Louis, MO). Resveratrol was dissolved in 
dimethyl sulfoxide (DMSO) and immediately used. Epidermal growth factor (EGF), and 
Interleukin-6 (IL-6) were from Prospec. Paclitaxel (PTX) was purchased from Tocris (Bristol, UK). 
The pan-caspase inhibitor Z-VAD-FMK was form Abcam (Cambridge, UK). The following 
reagents were obtained from GE Healthcare (Little Chalfont, UK): Hybond ECL membrane and 
ECL western blotting detection reagents. Fibronectin was from BD Biosciences (San Jose, CA). 
Primary antibodies were listed in (Supplementary Table 1). Secondary antibodies (HRP-conjugated) 
were all from Santa Cruz Biotechnology (Dallas, Texas). Cell culture media and reagents were 
purchased from EuroClone (Milano, Italy). All other reagents were from standard commercial 
sources and were of the highest grade available.  
The synthesis of resveratrol analogues was performed as previously described.
18
 Briefly, 1,4-diaryl-
1H-imidazoles Res_04, Res_08, Res_10, Res_15, Res_16, and Res_18, were prepared by a 
palladium-catalyzed Suzuki cross coupling reaction involving commercially available arylboronic 
acids and 4-bromo-1H-imidazole, followed by a copper-catalyzed Buchwald N-arylation of the 
resulting 4-aryl-1H-imidazoles with the required aryl bromides. On the contrary, 2,5-diaryl-1-
methyl-1H-imidazole Res_09, Res_11, Res_12, Res_13, Res_14, and Res_19 were regioselectively 
obtained by a palladium and copper promoted sequential C5/C2 double arylation of 1-methyl-1H-
imidazole with the required aryl bromides. All the compounds were isolated by flash 
chromatography on silica gel, and gave satisfactory mps, 
1
H-NMR, 
13
C-NMR, elemental analyses, 
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and EIMS data. GLC analyses showed that their chemical purity was higher than 97%. The 
chemical structure of analogues is shown in Supplementary Fig. 1. Analogues were all dissolved in 
in DMSO. 
 
Cell culture 
SKOV-3 human ovarian cancer cell line was grown in high-glucose Dulbecco’s modified Eagle’s 
medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 2-mM L-glutamine, 100 U 
mL
-1
 penicillin, 100 µg mL
-1
 streptomycin, in a humidified atmosphere of 5% CO2 at 37 °C. 
Normal Human Dermal Fibroblasts (NHDF) were kindly provided by dr. Tiziana Cocco and dr. 
Antonio Gaballo and maintained under standard culture conditions (complete DMEM, 5% CO2 at 
37 °C). MDA-231 cells were maintained under standard culture conditions (complete DMEM, 5% 
CO2 at 37 °C). 
Ascites were collected from chemotherapy-naïve ovarian cancer patients (n=3) diagnosed with 
serous adenocarcinoma and presented as stage III (FIGO classification) at the time of clinical 
intervention, as previously described.
19
 All patients provided written informed consent. 
 
Cell viability assay 
Cells were plated at 5 x 10
3
 / well in a 96-well plate and allowed to adhere to the plate overnight 
under the growth conditions described above. For determining cell viability, the MTT assay was 
used. After treatment, the culture medium was aspirated and 100 µl of RPMI-phenol free medium 
containing 10 µl of MTT stock solution, 5 mg mL
-1
 in phosphate-buffered saline (PBS) solution, 
was added to each well. After one hour of incubation, the MTT solution was removed and 100 µl of 
DMSO were added to dissolve MTT-formazan crystals. Absorbance of the converted dye was 
measured at a wavelength of 570 nm using an iMark microplate reader (BIORAD). The relative cell 
viability was expressed as a percentage of the untreated control group. The concentration of drug 
required to inhibit cell proliferation by 50% (IC50) was calculated using the Microsoft Excel 
software. Data were exported and analyzed using an Excel sheet and IC50 values were calculated 
by linear interpolation. IC values are expressed as mean ± standard deviation from at least ten 
independent experiments. 
 
Cell adhesion assay 
Cells were treated with resveratrol or analogues, maintained in suspension for 1 hour, and seeded 
onto 96-well plates coated with fibronectin (10 µg mL
-1
) or collagen type IV (10 µg mL
-1
) for 1 h at 
37 °C, at a density of 1×10
5
 cells/well. Bovine serum albumin (BSA) coating was used as negative 
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control. Briefly, non-adherent cells were removed by washing with PBS. Attached cells were fixed 
with 70% methanol for 10 minutes. Cells were stained with 0.02% crystal violet in 0.2% ethanol 
solution. Incorporated dye was dissolved in 10% acetic acid, and the absorbance was measured at 
560 nm. Each experiment was done in triplicate. 
 
Scratch wound assay 
Cells were cultured 24-well plate until confluence and then wounded using a 200 µL pipette tip in 
the middle of well. Three wounds were made for each sample, and migration distance was 
photographed and measured at zero time and after 24 h under an Olympus IX-51 microscope. The 
percentage (%) of open wound area was determined and the change in open wound area (%) at 24-
hour against zero time was calculated using the GraphPad PRISM software version 4.0. 
 
Western blot analysis 
Whole proteins were extracted in RIPA buffer (Cell Signaling, Danvers, MA) and quantified by the 
Bradford protein assay (BIORAD, Hercules, CA). Samples were separated by 12% SDS–PAGE and 
transferred to Hybond ECL nitrocellulose membranes (GE Healthcare, Little Chalfont, UK). The 
membranes were blocked with Blotto A (Santa Cruz, Dallas, Texas) at room temperature for 1 h, 
and incubated with the appropriate primary antibodies (see Supplementary Table 1) for 2 h at room 
temperature, as previously performed.
20
 After two washes with a solution of TBS containing 0.1% 
(v/v) tween 20 for 10 min, the membranes were incubated with secondary antibody HRP-
conjugated for 2 h at room temperature (standard dilution 1:2000). Blots were then developed using 
the Amersham ECL western blotting detection system (GE Healthcare, Little Chalfont, UK). 
Densitometric quantitation of at least three indipendent replicates was done using ImageJ software. 
 
Nucleic acid extraction, cDNA synthesis and qRT-PCR analysis 
Total RNA was isolated from SKOV-3 cells using the Illustra triplePrep kit (GE Healthcare, Little 
Chalfont, UK). First-strand cDNA was synthesized using 1 µg of total RNA, oligo(dT)18 and 
SuperScript III reverse transcriptase (Invitrogen, San Diego, CA) according to the manufacturer's 
protocol. The transcription profiles of CDH2, Slug, Vimentin, Zeb1, Zeb2, Sirt1, NRF1, TFAM, 
PPARGC1A genes after different treatment were analysed by using real time quantitative reverse 
transcription-PCR (qRT-PCR), which was performed in a 7500 Real-Time PCR System (Applied 
Biosystem, Warrington, UK). For the amplification reaction, a SYBR Green assay with iTaq 
Universal SYBR Green supermix (Bio-Rad, Hercules, CA) was performed in a reaction volume of 
25 µl. Expression levels of each mRNA were normalized to those of Rplp0 mRNA. Primers and 
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respective concentrations used for qRT-PCR are listed in Supplementary Table 2. The following 
amplification conditions were used: an initial denaturation step at 95 °C for 2 min, followed by 40 
cycles of 15 sec at 95 °C and 40 sec at 60 °C. Three replicates were performed for each experiment 
in addition to a no-template control included for each primer pair. Specificity of the PCR 
amplification was confirmed by dissociation curve analyses and the relative quantification of gene 
expression was established using the comparative 2
−∆∆CT
 method.  
 
Statistical analysis 
Data were expressed as mean ± SD. Statistical analyses was determined by unpaired Student’s t-test 
to compare between two groups and One-way ANOVA to compare three groups, analyzed using 
GraphPad PRISM software version 4.0. In all comparisons, p<0.05 was considered as statistically 
significant. 
 
 
Results 
The anti-proliferative effect of twelve analogues of resveratrol was evaluated in the human ovarian 
cancer cell line SKOV-3 using the MTT proliferation assay. Cells were treated with trans-
resveratrol, used as a reference compound, and its analogues at the concentrations of 100 µM, 50 
µM, and 25 µM, for 24 and 72 h (Fig. 1). Results show that all the analogues tested inhibited cell 
proliferation in a dose- and time-dependent manner (Fig. 1a). As shown in table 1, the IC50 (drug 
concentration required to reduce of 50% cell viability) values calculated for resveratrol and 
analogues demonstrated that resveratrol derivates exhibited a higher anti-proliferative activity 
compared to resveratrol treatment alone. In detail, at 100 µM and after 24 h of exposure, analogues 
4, 12, 13, 15, 16, and 19 produced the most pronounced effect with 100 % suppression of cellular 
growth (Fig. 1a). In contrast, cell viability of NHDF cells was not affected after resveratrol 
analogues treatment (Supplementary Figure 2). These data showed that analogues specifically 
reduced the growth of tumor cells but not normal cells in vitro. 
Biological effects of analogues on cancer cells were first assessed by investigating the expression of 
proteins related to the regulation of cell viability and proliferation, cytoskeletal rearrangement, and 
cell-cell adhesion. Changes in cell morphology (loss of front–back polarity and gain of organized 
compact cell island) were also evaluated microscopically. For this screening, we selected analogues 
4, 12, 13, 15, 16, and 19 that exhibited the greater anti-proliferative effect after 24 h of treatment. 
We previously demonstrated the reduced phosphorylation of Akt/Gsk, and Erk as a mechanism of 
cell growth inhibition mediated by resveratrol,
21
 leading to the hypothesis that these proteins may 
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also be a candidate targets for analogues in ovarian cancer models. Therefore, in the present study 
we treated SKOV-3 cells with resveratrol and analogues at 50 µM for 1 h, and compared the 
expression levels of selected proteins by western blotting. As shown in Fig. 1b, the phosphorylation 
levels of Akt, Gsk, Erk, and cofilin (Cof) were significantly reduced in SKOV-3 after treatment. We 
also demonstrated the reduced protein expression of N-cadherin, cyclin D1, β-catenin, and Bcl2 in 
SKOV-3 cells treated with analogues (Fig. 1b and Supplementary Figure 3). Collectively, these 
results imply that analogues-mediated anti-proliferative effects are mediated through the down-
regulation of survival and proliferation protein kinase signaling pathways such as Akt and Erk. 
In addition to these effects on cell proliferation, analogues demonstrated anti-tumor activities 
towards other cellular processes, including cell adhesion on extracellular matrix components (ECM) 
and cell migration. To demonstrate this, we tested the adhesion of SKOV-3 cells on cell culture 
plastic wells coated with two different ECM components, fibronectin and collagen IV, for 30 min 
and 4 h. As a control, an equal number of cells was added to uncoated wells or wells coated with 
BSA. Figure 2 showed the reduced adhesion to matrix proteins in SKOV-3 cells treated with 
resveratrol or analogues after 30 min and 4 h. As shown, there was a significant decrease of cell 
adhesion after treatment with analogues 4, 10, 12, 13, 14, 15, 16, and 19. 
In vitro scratch wound healing assays showed that the migration of SKOV-3 cells was significantly 
inhibited in the presence of analogues (Fig. 3a, b). The rate of wound closure was different 
depending on analogues exposure, but significantly reduced compared to EGF- and IL-6-exposed 
cells. Fig. 3d shows representative images of a scraping assay after resveratrol and analogues 
treatment. The upper panels show the cell position at 0 hours, while the other panels the gap closure 
after EGF and IL-6 treatment alone or in co-stimulation with resveratrol and selected analogues. 
Among the analogues tested, Res_4 showed the most pronounced effects on cell motility. We 
explored the molecular mechanisms behind Res_4 action, by examining the possible modulation of 
EGF downstream signalling pathways. To demonstrate this, we treated cancer cells with EGF alone 
or in co-stimulation with Res_4 at two different time points, and examined changes in the 
phosphorylation status of Erk (pErk). As shown in Fig 3c, Res_4 treatment caused a significant 
reduction of pErk levels as compared to EGF and EGF plus resveratrol treated cells. These results 
were consistent with the functional effects observed after wound assay. 
Suppression of cell migration, modulation of cytoskeletal components (i.e. cofilin), and down-
regulation of mesenchymal markers (i.e. N-cadherin) are reminiscent of a re-differentiation towards 
an epithelial phenotype, through the activation of a mesenchymal-epithelial transition (MET) 
program, which is the reverse process of the epithelial mesenchymal transition (EMT).
22
 We then 
examined whether analogues treatment would mediate a phenotypic and functional transition to 
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MET. To demonstrate this, we performed a RT-qPCR analysis of EMT markers including key 
EMT-activating transcription factors, Zeb1, Zeb2, and Slug, to assess transcriptomic changes 
induced after resveratrol and analogues treatment (Fig. 4). Among the analogues tested, we selected 
Res_15 for its enhanced anti-proliferative properties observed in the screening analysis. As shown, 
all five genes tested were down-regulated significantly after Res_15 treatment at 25 µM for 24 h. 
On the contrary, after Res treatment at 100 µM for 24 h, only Vimentin expression level was 
reduced whereas Zeb2 and Slug increased significantly their expression (Fig. 4a). Hence, Res_15 
treatment affected better than resveratrol the expression of EMT markers in SKOV-3 cells. After 
demonstrating the reduced expression levels of these genes after analogues treatment, we 
determined phenotypic modifications induced in SKOV-3 after treatment with resveratrol or 
analogues to observe a potential reversion to an epithelial status (Fig. 4b). The morphological 
appearance of treated SKOV-3 cells is illustrated in Fig. 4b. Despite the changes in EMT markers, 
the protein levels of the epithelial marker E-cadherin remained undetectable by western blotting 
(Fig. 1b), with no significant reversal of cell morphology (Fig. 4b). Similar results were obtained by 
treating the mesenchymal breast cancer model MDA-231 with analogues for 72 h and observing 
cell modifications by phase-contrast morphology (data not shown), leading to the conclusion that 
analogues reduced the expression of EMT markers and signalling EMT-related pathways without a 
complete molecular and phenotypic reversion into tight epithelial clusters.  
These enhanced anti-cancer properties prompted us to investigate the action of analogues respect to 
classical resveratrol targets. Previous studies described the ability of resveratrol to activate SIRT1 
and transcriptional factors that regulate mitochondrial biogenesis. We then investigated whether 
Res_15 is able to activate these markers by RT-qPCR. As shown, SIRT1 and PGC1α mRNA levels 
were both higher after resveratrol and Res_15 treatment, but significantly lower in Res_15 treated 
cells (Supplementary Figure 4). This suggests that the chemical structure of resveratrol is 
functionally important for driving the activation of these markers. 
The effects of analogues were also tested using ex-vivo models. Three primary cell lines were 
obtained form the ascitic fluid of from late-stage (III) ovarian serous adenocarcinoma cancer 
patients. These cells were cultured in vitro as monolayer or forced to growth in suspension using 
poly-HEMA coated-plates. We tested the anti-proliferative effect of analogues on these cell lines, 
these results are shown in Table 2. Reduced cell proliferation was demonstrated in ascitic cells 
compared with resveratrol treated cells. The most significant effects were obtained with Res_15, 
which was further studied for its ability to reduce growth is suspension and to reduce the expression 
of EMT markers (Fig. 5). Primary ovarian cancer cells were maintained in suspension using poly-
HEMA, which prevents cell attachment to the substratum and treated with resveratrol and Res_15 
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(Fig. 5a). As shown, in primary tumor cells and tumor cell lines, the percentage of trypan blue 
positive cells significantly increased after resveratrol and Res_15 exposure (Fig. 5a and b). 
Exposure of primary tumor cells to pan-caspase inhibitor Z-VAD-FMK, prevented resveratrol and 
Res_15 cell death suggesting that apoptosis is involved in the mechanism of cell death induced after 
resveratrol and its analogue exposure (Fig. 5a). The molecular mechanism underlying Res_15 
effects were investigated with a particular interest towards the regulation of EMT markers, cell 
cycle and apoptosis proteins. Res_15 reduced N-cadherin, Vimentin, Slug, Zeb1, Cyclin D1, Bcl2 
protein expression, and increased the expression of E-cadherin (Fig. 5c).  
EGF and IL-6 reduced the anti-cancer effect of the chemotherapeutic agent Paclitaxel (PTX) on 
tumor cells (Table 3). To verify if Res_15 analogue can interfere with this mechanism, we treated 
primary cells with PTX alone or in combination with EGF, IL-6, resveratrol and Res_15. As shown 
in Table 3, EGF and IL-6 in combination with PTX reduced the responsiveness to drug treatment, 
while resveratrol and Res_15 restore chemotherapy response. Both molecules act by targeting the 
EGF-induced pErk activation, as shown in Fig. 5d. 
 
Discussion 
We previously demonstrated the anticancer properties of trans-restricted analogues of resveratrol in 
vitro against 60 human tumor cell lines (National Cancer Institute-60 panel).
18
 Analogues displayed 
significant anti-proliferative potential across the NCI 60 panel. It remains to be determined the 
relationships among these analogues and resveratrol targets. In the present study, we provided 
further insights about the molecular targets of tested compounds using in vitro and ex vivo ovarian 
cancer cell models that we previously characterised for the resveratrol-mediated tumor suppressing 
activities. 
Our in vitro studies confirmed that resveratrol analogues reduced proliferation, cell-adhesion on 
ECM components, EGF- and IL-6-induced cell migration, EGF- and IL-6-induced chemoresistance, 
and anchorage independent growth of ovarian cancer cells. Resveratrol analogues affected cell 
proliferation in a dose and time dependent manner with an IC50 at 24 h and 72 h lower than 
resveratrol, without affecting the proliferation of normal cells. Among the analogues, Res_4, 
Res_12, Res_13, Res_15, Res_16, and Res_19 showed the lower IC50 at 24 h and were further 
evaluated by western blotting against some selected protein targets. These analogues belong to two 
main groups: Res_4, Res_15, Res_16 are 1,5-diaryl substituted imidazoles, while Res_12, Res_13, 
and Res_19 are 2,5-diaryl substituted 1-methylimidazoles. Our previous report suggested that the 
anti-proliferative effect of resveratrol was mediated through affecting Akt, Gsk, and Erk 
pathways.
21
 For this reason, we sought to investigate whether the same mechanism occurred also in 
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SKOV-3 cells treated with analogues. Our proposed model for analogues-induced antiproliferative 
effects in SKOV-3 is via the inhibition of Akt, Gsk, and Erk phosphorylation, and the reduced 
protein expression of cyclin D1, Bcl2 and β-catenin. Consistent with the observed morphological 
changes, a modification of cofilin phosphorylation was observed after treatment. Analogues also 
decreased the expression of N-cadherin but did not restore the expression of the epithelial marker E-
cadherin. N-cadherin mRNA down-regulation was confirmed by RT-qPCR, together with a 
significant effects of other EMT markers. This response was not observed after resveratrol 
treatment indicating a better activity of analogues against EMT markers. 
Overall, these data indicate the ability of analogues to be efficacious against several cellular targets, 
including EMT transcriptional regulators, a biological property that already characterises resveratrol 
and explains its multi-functional role in cell physiology. Importantly, analogues demonstrated a 
significant therapeutic potential at concentrations lower than those of resveratrol making these 
molecules closer to a possible clinical application.  
One of the physiological consequences of resveratrol treatment is the activation of energy sensing 
bioenergetics markers and pathways. We investigated the extent of analogues effects on these 
resveratrol targets. SIRT1 and PPARGC1A are typically activated after resveratrol treatment. The 
present data demonstrate that the activation at mRNA level of SIRT1 and PGC1α were lower in 
Res_15 treated cells compared to resveratrol treatment. This results can be explained by considering 
i) the lower concentration of Res_15 that we used to stimulate cells; ii) a close structure-activity 
relationship that is important to activate these pathways. This hypothesis is also supported by other 
studies that described the structure-activity relationships of various polyphenols including 
resveratrol.
23
 
Despite highly similar in their chemical structure, analogues demonstrate different biological 
properties. As shown in Fig. 1 and Supplementary Fig. 3, all six tested analogues exerted their 
effects by targeting cyclin D1, pErk (thr202/tyr204), pGsk (ser9), and pAkt (ser473). Three 
analogues (Res_15, Res_16, and Res_19) emerged in this screening because they showed greater 
effectiveness against some of the investigated targets (Supplementary Fig. 3), N-cadherin, β-
catenin, and Bcl2. These results provide a link between the chemical structure of analogues and 
their biological properties. This is also confirmed in the adhesion and wound experiments where 
analogues Res_4 showed greater efficacy compared to the other compounds.  
Of various resveratrol analogues tested, Res_15 showed the greater anti-proliferative effect, and 
was further assayed for its anti-cancer properties against patients-derived ex-vivo cultures isolated 
from ascetic fluids. Compared to SKOV-3, which are molecularly characterised by the expression 
of mesenchymal markers, ascites-derived cells exhibited an intermediate EMT phenotype as 
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evidenced by the simultaneous co-expression of epithelial and mesenchymal proteins. This is a 
more informative experimental system to detect changes in protein expression on a larger panel of 
EMT markers after analogues treatment. Overall, results confirmed the greater anti-cancer 
properties of Res_15 compared to resveratrol. Major mechanisms of action appear to involve the 
down-regulation of mesenchymal proteins with a significant up-regulation of the epithelial marker 
E-cadherin, suggesting that the intermediate mesenchymal phenotype can be partially reversed after 
treatment. This observation highlights the ability of resveratrol to target EMT/MET markers, but 
marks a difference compared to the experiments performed on SKOV-3. In this cell model, 
resveratrol and analogues were unable to restore E-cadherin expression. This means, that the 
mechanisms behind the repression of E-cadherin expression in SKOV-3 do not respond to 
resveratrol and analogues treatment. It remains unclear whether this was due to the incomplete 
repression of EMT transcriptional factors by Res_15 or due to the presence of an epigenetic 
mechanism of control. 
The MAPK pathway is closely associated with chemoresistance. The activation of this pathway is 
one of the mechanisms at the basis of PTX resistance.
21
 As demonstrated, analogues exhibited Erk 
inhibition. For this reason we tested the possibility to use analogues for overcoming EGF- and IL-6 
mediated resistance of cancer cells after PTX treatment. Here, we demonstrated the antagonizing 
effects of Res_15 on Erk phosphorylation mediated by EGF and IL-6 in combination with PTX in 
primary cells. 
Taken together, the current study highlights the potential of imidazole based resveratrol analogues, 
and indicates that Res_15 can be considered as a potential scaffold for the development of novel 
analogues with greater therapeutic potential against ovarian cancer. 
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Figure Legends 
 
 
Figure 1. Resveratrol analogues affect cancer cell viability. a) Skov-3 cells were treated with 
resveratrol or analogues at the indicated concentrations for 24 h or 72 h. Compounds were dissolved 
in DMSO and diluted to the desired concentration in DMEM medium. Control cells contained the 
vehicle only. Cell viability was calculated as described in Materials and Methods. Data shown 
represent the mean ± SD of three independent experiments and values were taken from at least six 
wells from each experiment. (b) E-cadherin, N-cadherin, Cyclin D1, Bcl-2, β-catenin, COF, pCOF, 
ERK, pERK, GSK, pGSK, Akt, pAkt protein expression was analyzed by western blot in SKOV-3 
cells after treatment of 1 h with resveratrol or its analogues at the concentration of 50 µM; α-tubulin 
was used as loading control. 
 
Figure 2. Resveratrol analogues reduce cancer cell adhesion on fibronectin- and collagen-coated 
plates. SKOV-3 were pre-treated with resveratrol or analogues for 1 h at the concentration of 50 µM 
and then seeded onto 10 µg mL
-1
 fibronectin-coated 96-well plates (a) or 10 µg mL
-1
 collagen-
coated 96-well plates (b). Data are mean ± SD of three independent experiments expressed as 
percentage comparing with the control without treatment. Asterisks indicate a significant difference 
compared to resveratrol-treated samples. Student’s t-test * p<0.05; ** p<0.01; *** p<0.001; 
 
Figure 3. Resveratrol analogues reduce the IL-6- and EGF-induced migration of cancer cells. a and 
b) Histograms show quantitative analysis of the percentage of gap reduction in SKOV-3 cancer 
cells after treatment with EGF 100 ng mL
-1
 or IL-6 20 ng mL
-1
 alone or in combination with 
resveratrol analogues. Vertical bars indicate the percentage (mean ± SD of three independent 
experiments) of wound closure at 24 h compared to the wound distance at time 0 in the control 
group. Asterisks indicate a significant difference compared to resveratrol plus EGF and IL-6 treated 
samples. Student’s t-test ** p<0.01; *** p<0.001. c) Representative immunoblots of Erk1/2 
phosphorylation in SKOV-3 cells treated for 15 minutes or 4 h with EGF, resveratrol and EGF, 
Res_04 and EGF. Asterisks indicate a significant difference compared to resveratrol-treated 
samples. d) Representative images of wound healing assay showing the reduced migration of 
SKOV-3 treated cells after EGF and IL-6 stimulation. 
 
Figure 4. a) Effects of Resveratrol and Res_15 treatment on gene expression in SKOV-3 cells.  
qPCR analysing the expression of EMT targets in SKOv-3 cells treated for 24 h with Res and 
Res_15 at the concentration of 100 uM and 25 uM, respectively. Data are represented as mean ± SD 
of three independent experiments. The only asterisks indicate a significant difference compared to 
control, whereas asterisks above a line represent a significant difference between resveratrol and 
Res_15 treated samples. One-way ANOVA analysis * p<0.05; ** p<0.01; *** p<0.001. b) 
Representative microscopic images of SKOV-3 cells treated with resveratrol or its analogues 
Res_04, Res_12, Res_13, Res_15, Res_16, Res_19 at the concentration of 25 µM and observed 
after 24 h of treatment (10x magnification). 
 
Figure 5. Multiple anti-cancer effects of resveratrol analogues on primary ovarian cancer cells. a) A 
representative phase contrast microscope image of ascites-derived cancer cells maintained in 
suspension using poly-Hema coated dishes (magnification 10x, scale bar 100 µM) and treated with 
resveratrol (II), or Res_15 (III). Control cells were treated with vehicle (I). Ascites-derived human 
tumor cells were maintained in suspension using poly-Hema coated dishes and with or without pre-
treatment of 50 mM ZVAD-fmk for 30 min prior to exposure to resveratrol or Res_15 for 72 h. The 
histograms show the percentage of positive cells for trypan blue staining. b) Human tumor cells 
were maintained in suspension using poly-Hema coated dishes and treated with resveratrol or 
Res_15 for 72 h. The histograms show the percentage of positive cells for trypan blue staining. Data 
Page 16 of 32Molecular BioSystems
17 
are the mean ± S.D of at least three independent experiments. Asterisks indicate a significant 
difference compared to res-treated samples. c) E-cadherin, N-cadherin, Vimentin, Slug, Zeb1, 
Cyclin D1, and Bcl2 protein expression was analyzed by western blot in ascites-derived ovarian 
cancer cells after treatment of 24 h with resveratrol or Res_15 at their IC50; α-tubulin was used as 
loading control. Densitometric quantification of three independent experiments (mean ± SD) was 
performed with ImageJ. Asterisks indicate a significant difference compared to resveratrol-treated 
samples. Student’s t-test * p<0.05; ** p<0.01; *** p<0.001. d) Erk 1/2, and pErk (thr202/tyr204) 
protein expression were analysed by western blotting in ascites-derived cancer cells (OvCa1) 
treated with PTX (6 nM), EGF (100 ng mL
-1
), Res (40 µM), and Res_15 (10 µM) after 4h of 
stimulation, as described. Asterisks indicate a significant difference compared to resveratrol-treated 
samples. 
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Table 1. IC50 values were calculated by performing dose-response experiments with resveratrol 
and analogues in SKOV-3 cells. 
Compound Chemical name 
IC50
a
 24h 
(µM) 
IC50 72h 
(µM) 
Res 3,5,4'-trans-trihydroxystilbene > 100 47.98 ± 1.31 
Res_04 
4-(4-methoxyphenyl)-1-(3,4,5-trimethoxyphenyl)-1H-
imidazole 
52.74 ± 1.4 24.29 ± 0.93 
Res_08 
4-(3,5-dimethoxyphenyl)-1-(3,4,5-trimethoxyphenyl)-1H-
imidazole 
> 100 44.5 ± 0.33 
Res_09 
5-(4-methoxyphenyl)-1-methyl-2-(3,4,5-trimethoxyphenyl)-
1H-imidazole 
> 100 45.1 ± 0.49 
Res_10 
4-(3,5-dimethoxyphenyl)-1-(4-methoxyphenyl)-1H-
imidazole 
> 100 39.9 ± 0.72 
Res_11 
2-(3,5-dimethoxyphenyl)-5-(4-methoxyphenyl)-1-methyl-
1H-imidazole 
> 100 32.6 ± 1 
Res_12 
2-(3,5-dimethoxyphenyl)-1-methyl-5-(3,4,5-
trimethoxyphenyl)-1H-imidazole 
54.51 ± 1.92 41.81 ± 0.50 
Res_13 
5-(3,5-dimethoxyphenyl)-2-(4-methoxyphenyl)-1-methyl-
1H-imidazole 
50.69 ± 2.38 42.51 ± 0.61 
Res_14 
2-(4-methoxyphenyl)-1-methyl-5-(3,4,5-trimethoxyphenyl)-
1H-imidazole 
> 100 44.4 ± 0.56 
Res_15 
1-(3,5-dimethoxyphenyl)-4-(4-methoxyphenyl)-1H-
imidazole 
52.99 ± 1.67 18.21 ± 0.87 
Res_16 
1-(4-methoxyphenyl)-4-(3,4,5-trimethoxyphenyl)-1H-
imidazole 
54.02 ± 3.83 43.9 ± 0.71 
Res_18 
1-(3,5-dimethoxyphenyl)-4-(3,4,5-trimethoxyphenyl)-1H-
imidazole 
> 100 41.33 ± 0.69 
Res_19 
5-(3,5-dimethoxyphenyl)-1-methyl-2-(3,4,5-
trimethoxyphenyl)-1H-imidazole 
50.77 ± 2.91 41.9 ± 0.32 
a The IC50 values (µM) are the concentrations corresponding to 50% inhibition of cell viability. IC50 values 
were determined by MTT assay after 24 h and 72 h of incubation. 
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Table 2. IC50 values were calculated by performing dose-response experiments with resveratrol and analogues in ascites derived tumor cells. 
 OvCa1 OvCa2 OvCa3 
Compound IC50
a
 24h (µM) IC50 72h (µM) IC50
a
 24h (µM) IC50 72h (µM) IC50
a
 24h (µM) IC50 72h (µM) 
Res > 100 40.45 ± 0.42 > 100 41.25 ± 1.25 > 100 38 ± 2.02 
Res_04 35.12 ± 1.20 18.50 ± 0.34 34.20 ± 1 20.10 ± 1.56 35.68 ± 0.56 20.55 ± 0.60 
Res_08 > 100 34.42 ± 0.78 > 100 33.50 ± 0.56 > 100 32.10 ± 1.60 
Res_09 > 100 38.2 ± 0.58 > 100 36.30 ± 1.10 > 100 35.70 ± 0.10 
Res_10 > 100 35.43 ± 0.42 > 100 34.40 ± 0.65 > 100 35.21 ± 1 
Res_11 > 100 28.2 ± 2.31 > 100 27 ± 0.40 > 100 25.76 ± 2.37 
Res_12 43.21 ± 1.92 38 ± 0.76 44.50 ± 2.20 38.42 ± 0.52 44.12 ± 1.10 39.70 ± 1.02 
Res_13 42.01 ± 1.22 37.31 ± 0.11 43 ± 1.45 36.55 ± 0.35 42.77 ± 0.50 36.44 ± 0.59 
Res_14 > 100 36.20 ± 1.60 > 100 35.10 ± 0.95 > 100 35.20 ± 0.47 
Res_15 34.31 ± 0.95 12.41 ± 1.25 35.27 ± 1.05 14.52 ± 1.45 36.59 ± 0.35 16.12 ± 0.30 
Res_16 39.34 ± 2.23 36.2 ± 1.23 38.24 ± 1.90 35.33 ± 2.03 35 ± 2.08 35.78 ± 1.75 
Res_18 > 100 31.35 ± 1.90 > 100 31 ± 0.90 > 100 32.05 ± 1.04 
Res_19 45.67 ± 2.56 35.60 ± 0.25 44.42 ± 2.40 34.76 ± 1.29 43.23 ± 1.66 33.39 ± 0.91 
a 
The IC50 values (µM) are the concentrations corresponding to 50% inhibition of cell viability. IC50 values were determined by MTT assay after 
24 h and 72 h of incubation. 
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Table 3. IC50 values for each combination were calculated by performing dose-response experiments in ascites derived tumor cells. 
 OvCA1 OvCA2 OvCA3 
Treatment group IC50 (nM) P value IC50 (nM) P value IC50 (nM) P value 
Paclitaxel 6.3 ± 1.1 / 4.4 ± 2 / 5.2 ± 0.9 / 
Paclitaxel / EGF 10.5 ± 1.5 *** 8.7 ± 0.8 *** 7.3 ± 1.1 *** 
Paclitaxel / EGF / Res 7.4 ± 0.6 / 5.8 ± 1.5 / 6.1 ± 0.5 / 
Paclitaxel / EGF / Res_15 6.1 ± 1.2 *** 4.2 ± 1 *** 4.8 ± 0.4 *** 
Paclitaxel / IL-6 9.1 ± 1.4 *** 8.1 ± 0.2 *** 7.9 ± 0.7 *** 
Paclitaxel / IL-6 / Res 7.1 ± 2 / 5.2 ± 0.1 / 6.2 ± 1.1 / 
Paclitaxel / IL-6 / Res_15 6.4 ± 0.5 *** 4.1 ± 0.2 *** 5.5 ± 0.4 *** 
Ascitic cells were treated with paclitaxel alone, paclitaxel plus resveratrol (40 µM), paclitaxel plus Res_15 (10 µM), plus EGF (100 ng mL
-1
), and 
IL-6 (10 ng mL
-1
) for 72 h. Cell viability was assayed using MTT. Data represent mean values ± S.D from three independent experiments. *P 
values, compared with paclitaxel alone. 
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Supplementary Table 1. List of antibodies used in western blotting. 
Antibody name Company Dilution 
Anti-Akt Santa Cruz Biotechnology (sc-5298) 1:1000 
Anti-Cofilin Santa Cruz Biotechnology (sc-33779) 1:1000 
Anti-phospho Cofilin (ser3) Santa Cruz Biotechnology (sc-21867-R) 1:1000 
Anti-Cyclin D1 Santa Cruz Biotechnology (sc-20044) 1:200 
Anti-E-cadherin Santa Cruz Biotechnology (sc-71009) 1:1000 
Anti-phospho-GSK3β Santa Cruz Biotechnology (sc-11757) 1:500 
Anti-N-cadherin Santa Cruz Biotechnology (sc-59987) 1:1000 
Anti-Slug Santa Cruz Biotechnology (sc-166902) 1:500 
Anti-Vimentin Santa Cruz Biotechnology (sc-7558) 1:500 
Anti-Zeb1 Santa Cruz Biotechnology (sc-25388) 1:500 
Anti-α Tubulin Santa Cruz Biotechnology (sc-23948) 1:2000 
Anti-β Catenin Santa Cruz Biotechnology (sc-1496) 1:1000 
Anti-Bcl2 Cell Signaling (D55G8) 1:1000 
Anti-GSK3β Cell Signaling (D5C5Z) 1:1000 
Anti-pospho-Akt (ser473) Cell Signaling (4051) 1:1000 
Anti-phospho-p44/42 MAPK (Erk 1/2) Cell Signaling (4695) 1:2000 
Anti-phospho-p44/42 MAPK (Erk 1/2) 
(thr202/tyr204) 
Cell Signaling (4370) 1:2000 
Anti-phospho-GSK3 (tyr279/tyr216) Millipore (05-413) 1:500 
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Supplementary Table 2. Oligonucleotides used for Real time PCR analysis. 
Gene 
Accession number 
(NCBI) 
Primer 5′-3′ bp 
CDH2 NM_001792.4 
N-cad F: CAGGAAAAGTGGCAAGTGGC 
N-cad R: AGGAAAAGGTCCCCTGGAG 
197 
VIM NM_003380.3 
VIM F: TGGCCGACGCCATCAACACC 
VIM R: CACCTCGACGCGGGCTTTGT 
227 
ZEB1 NM_001174096.1 
ZEB1 F: GGCCCCAGGTGTAAGCGCAG 
ZEB1 R: CTGTTGGCAGGTCATCCTC 
181 
ZEB2 NM_014795.3 
ZEB2 F: AAGCCAGGGACAGATCAGC 
ZEB2 R: GCAGTTTGGGCACTCGTAAG 
156 
SLUG NM_003068.4 
Slug F: CAACGCCTCCAAAAAGCCAA 
Slug R: ACTCACTCGCCCCAAAGATG 
229 
NRF1 NM_005011.3 
NRF  F: CCGTTGCCCAAGTGAATTAT 
NRF  R: ACTGTAGCTCCCTGCTGCAT 
181 
PPARGC1A NM_013261.3 
PGC1aF: GCTGACAGATGGAGACGTGA 
PGC1aR: TGCATGGTTCTGGGTACTGA 
178 
SIRT1 NM_001142498.1 
sirt F: TGTTGGTTCTAGTACTGGGG 
sirt R: CCTCAGCGCCATGGAAAATG 
164 
TFAM NM_001270782.1 
Tfam F: CCGAGGTGGTTTTCATCTGT 
Tfam R: ACGCTGGGCAATTCTTCTAA 
147 
Rplp0 NM_001697.2 
36B4 F: TCGACAATGGCAGCATCTAC 
36B4 R: ATCCGTCTCCACAGACAAGG 
191 
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Supplementary Figure Legends 
 
Supplementary Figure 1. Chemical structures of resveratrol analogues. They belong to two 
distinct classes of bis-arylated imidazoles: 1,5-diaryl substituted imidazoles (Res_04, Res_08, 
Res_10, Res_15, Res_18), and 2,5-diaryl substituted 1-methylimidazoles (Res_09, Res_11, Res_12, 
Res_13, Res_14, Res_19). 
 
Supplementary Figure 2. Resveratrol analogues effects on NHDF cell proliferation. Cells were 
treated with resveratrol or analogues at 25 µM for 72 h. Data shown represent the mean ± SD of 
three independent experiments and values were taken from at least six wells from each experiment. 
 
Supplementary Figure 3. Densitometric analysis of western blotting data. Results (mean ± SD; n = 
3) are expressed as fold change of CTR values, and represent the ratio between N-cadherin, Cyclin 
D1, β-catenin, Bcl2, and α-tubulin levels. pCof, pErk, pGsk, and pAkt were normalised over total 
Cof, Erk, Gsk, Akt. Data were analyzed by Student's t-test. * p<0.05; ** p<0.01; *** p<0.001 as 
compared with resveratrol treated cells. 
 
Supplementary Figure 4. qPCR analysis on the expression of resveratrol targets in SKOV-3 cells 
treated for 24 h with Res and Res_15 at the concentration of 100 uM and 25 uM, respectively. Data 
are represented as mean ± SD of three independent experiments. The only asterisks indicate a 
significant difference compared to control, whereas asterisks above a line represent a significant 
difference between resveratrol and Res_15 treated samples. One-way ANOVA analysis * p<0.05; 
** p<0.01; *** p<0.001. 
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